Samuel S. Lee

Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis.

M. Vachon, B. Conway, J. Feld, 2021, Canadian liver journal.

Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants

M. Vachon, B. Conway, J. Feld, 2020, BMC Public Health.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

V. de Lédinghen, P. Angus, K. Reddy, 2015, JAMA.

Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C

C. Ross, B. Carleton, G. Wright, 2022, Liver international : official journal of the International Association for the Study of the Liver.

A pilot study of the CY‐1899 T‐cell vaccine in subjects chronically infected with hepatitis B virus

A. Sette, G. Minuk, T. Wright, 1999, Hepatology.

Impact of direct‐acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings

Zeny Z. Feng, V. Martel-Laferrière, M. Krahn, 2023, Liver international : official journal of the International Association for the Study of the Liver.

Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.

M. Vachon, B. Conway, J. Feld, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

V. de Lédinghen, G. Dore, S. Pol, 2015, Gastroenterology.

Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.

M. Sherman, P. Marotta, K. Peltekian, 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Transplant immunosuppressive agents in non‐transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus

U. Steinbrecher, P. Marotta, E. Yoshida, 2005, Liver international : official journal of the International Association for the Study of the Liver.